- Home
- KPLT vs TPST Comparison
KPLT vs TPST Comparison
Compare KPLT & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPLT
- TPST
- Stock Information
- Founded
- KPLT 2012
- TPST 2011
- Country
- KPLT United States
- TPST United States
- Employees
- KPLT N/A
- TPST N/A
- Industry
- KPLT Diversified Commercial Services
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- KPLT Consumer Discretionary
- TPST Health Care
- Exchange
- KPLT Nasdaq
- TPST Nasdaq
- Market Cap
- KPLT 52.2M
- TPST 42.3M
- IPO Year
- KPLT N/A
- TPST N/A
- Fundamental
- Price
- KPLT $5.75
- TPST $3.40
- Analyst Decision
- KPLT Hold
- TPST Hold
- Analyst Count
- KPLT 1
- TPST 2
- Target Price
- KPLT $10.00
- TPST $12.50
- AVG Volume (30 Days)
- KPLT 128.6K
- TPST 116.3K
- Earning Date
- KPLT 11-12-2025
- TPST 11-05-2025
- Dividend Yield
- KPLT N/A
- TPST N/A
- EPS Growth
- KPLT N/A
- TPST N/A
- EPS
- KPLT N/A
- TPST N/A
- Revenue
- KPLT $280,839,000.00
- TPST N/A
- Revenue This Year
- KPLT $22.88
- TPST N/A
- Revenue Next Year
- KPLT $10.98
- TPST N/A
- P/E Ratio
- KPLT N/A
- TPST N/A
- Revenue Growth
- KPLT 16.15
- TPST N/A
- 52 Week Low
- KPLT $5.08
- TPST $3.30
- 52 Week High
- KPLT $24.34
- TPST $13.65
- Technical
- Relative Strength Index (RSI)
- KPLT 25.89
- TPST 18.20
- Support Level
- KPLT $5.50
- TPST $8.51
- Resistance Level
- KPLT $6.43
- TPST $9.75
- Average True Range (ATR)
- KPLT 0.93
- TPST 1.01
- MACD
- KPLT -0.12
- TPST -0.68
- Stochastic Oscillator
- KPLT 8.63
- TPST 1.73
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.